Norovirus: Vaxart’s oral vaccine met all primary/secondary endpoints in Phase 1b study

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced positive topline results from the randomized, double-blind, placebo-controlled Phase 1b safety, immunogenicity and interference study with its oral tableted bivalent norovirus vaccine in healthy adults. The study met all primary endpoints for safety and ["]

The post Norovirus: Vaxart's oral vaccine met all primary/secondary endpoints in Phase 1b study appeared first on Outbreak News Today.